Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues
Total revenues	$ 709	$ 1,222
Cost of revenues	488	725
Gross profit	221	497
Operating expenses
General and administrative	11,401	8,119
Research and development	9,066	9,370
Sales and marketing	783	1,051
Total operating expenses	21,250	18,540
Loss from operations	(21,029)	(18,043)
Other (expense) and income
Lawsuit expense	(30)	(1,398)
Other refundable tax credits	23	306
Other (expense) income, net	(377)	300
Total other expenses, net	(384)	(792)
Net loss	(21,413)	(18,835)
Dividend attributable to warrant down round feature	(798)
Net loss attributable to common stockholders	$ (22,211)	$ (18,835)
Basic net loss per share (in Dollars per share)	$ (1.02)	$ (0.9)
Basic weighted average common shares outstanding (in Shares)	21,734,901	20,969,032
Grant revenue
Revenues
Total revenues	$ 41	$ 282
Clinical trial revenue
Revenues
Total revenues	$ 668	$ 940